Advertisement

Staging of Small-Cell Lung Cancer

  • Girish S. Shroff
  • Neda Kalhor
  • Reza J. Mehran
  • Patricia M. de Groot
  • Brett W. Carter
Chapter

Abstract

Small-cell lung cancer (SCLC) is the most common and most aggressive pulmonary neuroendocrine malignancy. SCLCs account for approximately 13% of all lung cancers and are characterized by rapid growth, early development of metastatic disease, dramatic initial response to chemotherapy and radiation therapy, and frequent association with paraneoplastic syndromes. Computed tomography (CT) and positron-emission tomography (PET)/CT are the imaging modalities routinely used in the evaluation of patients with SCLC. On imaging, SCLC usually manifests as a large centrally located lung mass or as mediastinal or mediastinal and hilar lymphadenopathy. Most patients have metastatic disease at presentation. Historically, the Veterans Administration Lung Study Group (VALG) staging system has been used to stage SCLC. More recently, it has been recommended by the International Association for the Study of Lung Cancer (IASLC) that the tumor, node, metastasis (TNM) staging system replace the VALG staging system. Despite characteristic responsiveness to initial therapy, disease invariably recurs and the overall prognosis remains poor.

Keywords

Small-cell lung cancer (SCLC) Neuroendocrine malignancy (TNM) staging system Computed tomography (CT) Positron-emission tomography/computed tomography (PET/CT) 

References

  1. 1.
    Brownson RC, Chang JC, Davis JR. Gender and histologic type variations in smoking-related risk of lung cancer. Epidemiology. 1992;3:61–4.CrossRefPubMedGoogle Scholar
  2. 2.
    Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24:4539–44.CrossRefPubMedGoogle Scholar
  3. 3.
  4. 4.
    Albain KS, Crowley JJ, Livingston RB. Long-term survival and toxicity in small cell lung cancer. Expanded Southwest Oncology Group experience. Chest. 1991;99:1425–32.CrossRefPubMedGoogle Scholar
  5. 5.
    Lassen U, Osterlind K, Hansen M, et al. Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients. J Clin Oncol. 1995;13:1215–20.CrossRefPubMedGoogle Scholar
  6. 6.
    Osterlind K, Hansen HH, Hansen M, et al. Long-term disease-free survival in small-cell carcinoma of the lung: a study of clinical determinants. J Clin Oncol. 1986;4:1307–13.CrossRefPubMedGoogle Scholar
  7. 7.
    Tai P, Tonita J, Yu E, et al. Twenty-year follow-up study of long-term survival of limited-stage small-cell lung cancer and overview of prognostic and treatment factors. Int J Radiat Oncol Biol Phys. 2003;56:626–33.CrossRefPubMedGoogle Scholar
  8. 8.
    Watson WL, Berg JW. Oat cell lung cancer. Cancer. 1962;15:759–68.CrossRefPubMedGoogle Scholar
  9. 9.
    Pietanza MC, Krug LM, Wu AJ, et al. Small cell and neuroendocrine tumors of the lung. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. Devita, Hellman, and Rosenberg’s cancer: principles & practice of oncology. 10th ed. Philadelphia: Wolters Kluwer; 2015. p. 536–57.Google Scholar
  10. 10.
    Hollen PJ, Gralla RJ, Kris MG, et al. Quality of life assessment in individuals with lung cancer: testing the lung cancer symptom scale (LCSS). Eur J Cancer. 1993;29A(Suppl 1):S51–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Cohen MH, Matthews MJ. Small cell bronchogenic carcinoma: a distinct clinicopathologic entity. Semin Oncol. 1978;5:234–43.PubMedGoogle Scholar
  12. 12.
    Sculier JP, Evans WK, Feld R, et al. Superior vena caval obstruction syndrome in small cell lung cancer. Cancer. 1986;57:847–51.CrossRefPubMedGoogle Scholar
  13. 13.
    Seute T, Leffers P, ten Velde GP, et al. Neurologic disorders in 432 consecutive patients with small cell lung carcinoma. Cancer. 2004;100:801–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG, editors. WHO classification of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press; 2015.Google Scholar
  15. 15.
    Gandhi L, Johnson BE. Paraneoplastic syndromes associated with small cell lung cancer. J Natl Compr Cancer Netw. 2006;4:631–8.CrossRefGoogle Scholar
  16. 16.
    Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. WHO classification of tumours pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004.Google Scholar
  17. 17.
    Travis WD. Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas. Mod Pathol. 2012;25(Suppl 1):S18–30.CrossRefPubMedGoogle Scholar
  18. 18.
    Travis WD. Advances in neuroendocrine lung tumors. Ann Oncol. 2010;21(Suppl 7):vii65–71.CrossRefPubMedGoogle Scholar
  19. 19.
    Kim KW, Krajewski KM, Jagannathan JP, et al. Cancer of unknown primary sites: what radiologists need to know and what oncologists want to know. AJR Am J Roentgenol. 2013;200:484–92.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Kreyberg L. Histological lung cancer types. A morphological and biological correlation. Acta Pathol Microbiol Scand Suppl. 1962;157:1–92.PubMedGoogle Scholar
  21. 21.
    Hirsch FR, Matthews MJ, Aisner S, et al. Histopathologic classification of small cell lung cancer. Changing concepts and terminology. Cancer. 1988;62:973–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10:1243–60.CrossRefPubMedGoogle Scholar
  23. 23.
    Rosado-de-Christenson ML, Templeton PA, Moran CA. Bronchogenic carcinoma: radiologic-pathologic correlation. Radiographics. 1994;14:429–46.CrossRefPubMedGoogle Scholar
  24. 24.
    Carter BW, Glisson BS, Truong MT, et al. Small cell lung carcinoma: staging, imaging, and treatment considerations. Radiographics. 2014;34:1707–21.CrossRefPubMedGoogle Scholar
  25. 25.
    Pearlberg JL, Sandler MA, Lewis JW Jr, et al. Small-cell bronchogenic carcinoma: CT evaluation. AJR Am J Roentgenol. 1988;150:265–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Whitley NO, Fuks JZ, McCrea ES, et al. Computed tomography of the chest in small cell lung cancer: potential new prognostic signs. AJR Am J Roentgenol. 1984;142:885–92.CrossRefPubMedGoogle Scholar
  27. 27.
    Kazawa N, Kitaichi M, Hiraoka M, et al. Small cell lung carcinoma: eight types of extension and spread on computed tomography. J Comput Assist Tomogr. 2006;30:653–61.CrossRefPubMedGoogle Scholar
  28. 28.
    Yabuuchi H, Murayama S, Sakai S, et al. Resected peripheral small cell carcinoma of the lung: computed tomographic-histologic correlation. J Thorac Imaging. 1999;14:105–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Podoloff DA, Ball DW, Ben-Josef E, et al. NCCN task force: clinical utility of PET in a variety of tumor types. J Natl Compr Cancer Netw. 2009;7(Suppl 2):S1–26.CrossRefGoogle Scholar
  30. 30.
    Bradley JD, Dehdashti F, Mintun MA, et al. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol. 2004;22:3248–54.CrossRefPubMedGoogle Scholar
  31. 31.
    Fischer BM, Mortensen J, Langer SW, et al. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol. 2007;18:338–45.CrossRefPubMedGoogle Scholar
  32. 32.
    Kalemkerian GP, Gadgeel SM. Modern staging of small cell lung cancer. J Natl Compr Cancer Netw. 2013;11:99–104.CrossRefGoogle Scholar
  33. 33.
    Schumacher T, Brink I, Mix M, et al. FDG-PET imaging for the staging and follow-up of small cell lung cancer. Eur J Nucl Med. 2001;28:483–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Kamel EM, Zwahlen D, Wyss MT, et al. Whole-body 18F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med. 2003;44:1911–7.PubMedGoogle Scholar
  35. 35.
    Blum R, MacManus MP, Rischin D, et al. Impact of positron emission tomography on the management of patients with small cell lung cancer: preliminary experience. Am J Clin Oncol. 2004;27:164–71.CrossRefPubMedGoogle Scholar
  36. 36.
    Arslan N, Tuncel M, Kuzhan O, et al. Evaluation of outcome prediction and disease extension by quantitative 2-deoxy-2-[18F] fluoro-D-glucose with positron emission tomography in patients with small cell lung cancer. Ann Nucl Med. 2011;25:406–13.CrossRefPubMedGoogle Scholar
  37. 37.
    Chong S, Lee KS, Kim BT, et al. Integrated PET/CT of pulmonary neuroendocrine tumors: diagnostic and prognostic implications. AJR Am J Roentgenol. 2007;188:1223–31.CrossRefPubMedGoogle Scholar
  38. 38.
    Pandit N, Gonen M, Krug L, et al. Prognostic value of [18F]FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging. 2003;30:78–84.CrossRefPubMedGoogle Scholar
  39. 39.
    Ravenel JG, Rosenzweig KE, Kirsch J, et al. ACR appropriateness criteria non-invasive clinical staging of bronchogenic carcinoma. J Am Coll Radiol. 2014;11:849–56.CrossRefPubMedGoogle Scholar
  40. 40.
    Jackman DM, Johnson BE. Small-cell lung cancer. Lancet. 2005;366:1385–96.CrossRefPubMedGoogle Scholar
  41. 41.
    Shepherd FA, Crowley J, Van Houtte P, et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol. 2007;2:1067–77.CrossRefPubMedGoogle Scholar
  42. 42.
    Stahel RA, Ginsberg R, Havemann K, et al. Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer. 1989;5:119–26.CrossRefGoogle Scholar
  43. 43.
    Nicholson AG, Chansky K, Crowley J, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11:300–11.CrossRefPubMedGoogle Scholar
  44. 44.
    NCCN Clinical Practice Guidelines in Oncology, Small Cell Lung Cancer, Version 3.2017-February 23, 2017. NCCN.org. Accessed 21 April 2017.
  45. 45.
    Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327:1618–24.CrossRefPubMedGoogle Scholar
  46. 46.
    Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol. 1992;10:890–5.CrossRefPubMedGoogle Scholar
  47. 47.
    Owonikoko TK, Behera M, Chen Z, et al. A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J Thorac Oncol. 2012;7:866–72.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Arriagada R, Le Chevalier T, Rivière A, et al. Patterns of failure after prophylactic cranial irradiation in small-cell lung cancer: analysis of 505 randomized patients. Ann Oncol. 2002;13:748–54.CrossRefPubMedGoogle Scholar
  49. 49.
    Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341:476–84.CrossRefPubMedGoogle Scholar
  50. 50.
    Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357:664–72.CrossRefPubMedGoogle Scholar
  51. 51.
    Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(5):663–71.CrossRefPubMedGoogle Scholar
  52. 52.
    Lad T, Piantadosi S, Thomas P, et al. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest. 1994;106(6 Suppl):320S–3S.CrossRefPubMedGoogle Scholar
  53. 53.
    Schneider BJ, Saxena A, Downey RJ. Surgery for early-stage small cell lung cancer. J Natl Compr Cancer Netw. 2011;9:1132–9.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Girish S. Shroff
    • 1
  • Neda Kalhor
    • 2
  • Reza J. Mehran
    • 3
  • Patricia M. de Groot
    • 1
  • Brett W. Carter
    • 1
  1. 1.Department of Diagnostic RadiologyMD Anderson Cancer CenterHoustonUSA
  2. 2.Department of PathologyMD Anderson Cancer CenterHoustonUSA
  3. 3.Department of Thoracic and Cardiovascular SurgeryMD Anderson Cancer CenterHoustonUSA

Personalised recommendations